Standout Papers

Edoxaban for the Treatment of Cancer-Associated Venous Thromboemboli... 2013 2026 2017 2021 1.0k
  1. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism (2017)
    Gary E. Raskob, Nick van Es et al. New England Journal of Medicine
  2. Idarucizumab for Dabigatran Reversal (2015)
    Charles V. Pollack, Paul A. Reilly et al. New England Journal of Medicine
  3. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation (2015)
    Hein Heidbüchel, Peter Verhamme et al. EP Europace
  4. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation (2013)
    Hein Heidbüchel, Peter Verhamme et al. EP Europace
  5. Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism (2017)
    Jeffrey I. Weitz, Anthonie W.A. Lensing et al. New England Journal of Medicine
  6. Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis (2014)
    Harry R. Büller, Claudette Bethune et al. New England Journal of Medicine
  7. Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial (2011)
    Drahomir Aujesky, Pierre‐Marie Roy et al. The Lancet
  8. Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease (2018)
    Sonia S. Anand, François Caron et al. Journal of the American College of Cardiology
  9. Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians (2017)
    Jonathan Douxfils, Walter Ageno et al. Journal of Thrombosis and Haemostasis
  10. Abelacimab for Prevention of Venous Thromboembolism (2021)
    Peter Verhamme, B. Alexander Yi et al. New England Journal of Medicine

Immediate Impact

4 from Science/Nature 61 standout
Sub-graph 1 of 17

Citing Papers

Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation
2025 Standout
Stroke
2024 Standout
10 intermediate papers

Works of Peter Verhamme being referenced

Hemostatic Efficacy and Anti-FXa (Factor Xa) Reversal With Andexanet Alfa in Intracranial Hemorrhage: ANNEXA-4 Substudy
2021
EHRA Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary†
2013
and 4 more

Author Peers

Author Last Decade Papers Cites
Peter Verhamme 6876 5355 2250 343 12.7k
Francesco Dentali 6926 7698 3465 192 12.9k
Suzanne C. Cannegieter 6864 7201 2832 325 13.7k
Stavros Konstantinides 9006 10828 2562 436 17.5k
Thomas L. Ortel 4782 5376 3980 275 15.1k
Richard H. White 5431 8299 3863 241 15.5k
Armando D’Angelo 2471 2707 1851 188 9.0k
Kenneth A. Bauer 6284 7435 2961 200 13.4k
Christoph Bode 7165 2282 3670 415 12.4k
Beverley J. Hunt 3351 4364 4519 337 18.6k
Bernd Jilma 4750 2109 2373 554 16.4k

All Works

Loading papers...

Rankless by CCL
2026